Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive cannabidiol therapy in CDKL5 deficiency disorder
2021-001959-13Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabidiol in CDKL5 deficiency disorder (CDD) and epilepsy, sponsored by Policlinico Gemelli. Primary endpoint: Primary endpoint of this study. Started Jul 2021; status: completed.
02
Drugs
cannabidiol
03
Conditions
CDKL5 deficiency disorder (CDD)epilepsy
Beyond the preview
Go deeper on 2021-001959-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001959-13.